Company Profile

Integral Molecular Inc
Profile last edited on: 1/14/2019      CAGE: 3PJG4      UEI: DY9KSWE8EJB8

Business Identifier: Membrane protein therapeutics; antibodies for membrane proteins.
Year Founded
2001
First Award
2002
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3711 Market Street Suite 900
Philadelphia, PA 19104
   (215) 966-6018
   info@integralmolecular.com
   www.integralmolecular.com
Location: Single
Congr. District: 03
County: Philadelphia

Public Profile

Integral Molecular was founded to further membrane proteins research conducted at the University of Pennsylvania 1997-2000 that resulted in manuscripts published in the journals Science, PNAS, and Journal of Virology. Working with pharmaceutical, biotechnology, and academic customers and collaborators since its founding, Integral's has designed products to be used throughout the drug discovery process, primarily in the identification and optimization of chemical compounds and in the development of antibodies against integral membrane proteins. With a pipeline of therapeutic antibodies for membrane protein targets, including GPCRs, ion channels, and transporters, the company offers Lipoparticles, a technology that facilitates the discovery of drugs against integral membrane proteins. Its products are used throughout the drug discovery process, focusing on the identification and optimization of chemical compounds and in the development of antibodies against integral membrane proteins.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Benjamin J Doranz -- President

  James Augusterfer -- Controller

  Ross Chambers -- Director Of Antibody Discovery

  Dawn Eringis -- Business Development Officer

  Tiffani Greene

  Eva Harris

  Shahram Hejazi -- Chair of Advisory Board

  Cheryl Paes -- Director of Sales and Marketing Operations

  Martin Phillips -- Advisor

  Joseph Benjamin Rucker -- VP of R&D

  Sharon H Willis -- VP of Tech. Sales and Customer Relations